Novel p53 gene-based therapy boosts immune system and reduces tumor size
Use of a novel gene-based therapy before breast cancer surgery reduced tumor size by nearly 80 percent on average, researchers from The University of Texas M. D. Anderson Cancer Center report at the annual San Antonio Breast Cancer Symposium meeting.
The therapy, known as Advexin, also showed evidence that the p53 protein it was delivering was actually being replaced in the targeted tumors, and that the treatment produced beneficial and possibly sustained local immune responses in the patients tested.
"We have nice evidence of a double-acting mechanism of gene therapy, something that has not been seen before in patients treated with only chemotherapy," says Massimo Cristofanilli, M.D., an associate professor in the Department of Breast Medical Oncology. About half of patients with locally advanced breast cancer have mutations in their p53 gene, which plays a critical role in suppressing cancer development. The Advexin therapy uses an adenovirus vector to supply normal p53 genes in very high concentrations to cancer cells.
In the study, 12 eligible patients with locally advanced breast cancer, each of whom had large tumors (an average of eight centimeters, larger than a silver dollar), received several injections of Advexin directly into the tumor, followed by a course of chemotherapy. The combination therapy resulted in significantly smaller tumors - all shrunk by more than 50 percent to a mean size of 1.78 centimeters - which meant that many of the patients could choose lumpectomy (removal only of the tumor) instead of mastectomy (removal of the breast). Tumors in patients lymph nodes also decreased in size.
After surgery, researchers examined the excised tumors and found all of the specimens showed extensive infiltration of T-lymphocytes, which are components of the immune system known to be involved in fighting cancer cells, as well as higher levels of normal p53 mRNA, suggesting that there may be an increase in the p53 protein, which guards against cancer development and progression.
Twenty months following surgery, cancer came back in two of 12 patients, and one had died from the disease. "This is a better response than is typically seen in most patients with locally advanced breast cancer," Cristofanilli says.
Cristofanilli says further studies are planned, including testing Advexin head-to-head with chemotherapy.
Introgen, the independent company that makes the drug, develops biopharmaceutical products designed to induce therapeutic proteins for the treatment of cancer and other diseases. Introgen holds a licensing agreement with M. D. Anderson to commercialize products based on licensed technologies, and has the option to license future technologies under sponsored research agreements. The University of Texas System Board of Regents owns stock in Introgen. These arrangements are managed in accordance with M. D. Andersons conflict of interest policies.
Nancy Jensen | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...